Rockeby Biomed

Rockeby Biomed is a biotechnology company based in Singapore that specializes in the research, development, and commercialization of rapid diagnostic test kits for infectious diseases. The company is best known for its flagship product, CanDia5, a rapid point-of-care test for systemic Candidiasis that provides results in minutes rather than days. Rockeby also developed diagnostic tools for Avian Influenza (H5N1) and other fungal infections, targeting the global healthcare market's need for timely intervention. Founded in 2002, the company focused on providing cost-effective and accessible diagnostic solutions to improve patient outcomes in the field of fungal and viral infections. The company was previously listed on the Australian Securities Exchange (ASX) before being delisted in 2011 following its acquisition by Abecha, a subsidiary of SmartTrans Holdings.